Director Jason Aryeh filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 700 shares of Ligand Pharmaceuticals Inc Class B common stock originally acquired in 2019.

Key Highlights

  • Filer and role: Jason Aryeh, a director of Ligand Pharmaceuticals Inc, submitted the notice.
  • Shares proposed for sale: 700 shares of Class B common stock, with an aggregate market value of $221,595.09 according to the filing.
  • Shares outstanding: The filing lists 20,002,986 shares of Class B common stock outstanding.
  • Acquisition history: The shares were acquired through secondary market purchases between May 14, 2019, and July 30, 2019, with cash payment.
  • Broker named: Wells Fargo Clearing Services, 1 North Jefferson Avenue, St. Louis, MO 63103, is identified as the broker.
  • No prior sales reported: The filing indicates nothing to report for securities sold during the past three months.
  • Approximate sale date: November 2, 2026, on Nasdaq.

Jason Aryeh's Proposed Class B Share Sale at Ligand Pharmaceuticals

According to the Form 144 filing, Jason Aryeh, identified as a director of Ligand Pharmaceuticals Inc (NASDAQ:LGND), filed notice of a proposed sale of 700 shares of the company's Class B common stock. The filing lists an aggregate market value of $221,595.09 for the proposed transaction, with an approximate sale date of November 2, 2026. The broker designated to handle the transaction is Wells Fargo Clearing Services in St. Louis, Missouri.

The filing discloses that the 700 shares were acquired through secondary market purchases paid for in cash. The filing's remarks section states that "shares were acquired between 05/14/2019 to 07/30/2019," with the primary acquisition date listed as May 14, 2019. As of the filing date, the total Class B common shares outstanding are reported as 20,002,986.

The filing notes no sales of Ligand securities by Aryeh during the three months preceding this notice. By signing the Form 144, Aryeh represented, as the filing states, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."

What Was Disclosed

A Form 144 notice was filed by Ligand Pharmaceuticals director Jason Aryeh on November 2, 2026, covering a proposed sale of 700 Class B common shares with an aggregate market value of $221,595.09, originally purchased via secondary market transactions in 2019.